

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.

杭州九源基因生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2566)

**VOLUNTARY ANNOUNCEMENT
REPURCHASE OF H SHARES BY THE COMPANY
UNDER THE REPURCHASE MANDATE**

This announcement is made by Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the “**Company**”) on a voluntary basis.

References are made to (i) the circulars of the Company dated April 25, 2025 and April 24, 2026 in relation to, among other things, the grant of general mandates to repurchase H Shares as approved under the respective resolutions (collectively, the “**Repurchase Mandate**”); and (ii) the announcement of the poll results of the annual general meeting of the Company (the “**AGM**”) held on June 11, 2025, the announcement of repurchase of H Shares by the Company under the Repurchase Mandate dated December 2, 2025 and the announcement of the poll results of the AGM held on June 15, 2026 (the “**Announcements**”). Unless otherwise defined herein, all capitalized terms used herein shall have the same meanings as those defined in the Circulars and Announcements.

The Shareholders resolved at the AGM held on June 15, 2026 to grant the repurchase mandate to the Board to, by reference to the market conditions and funding arrangements, repurchase the H Shares not exceeding 10.0% of the total number of the H Shares in issue (excluding treasury Shares, if any) as of June 15, 2026 (i.e., a total of 24,151,640 H Shares). The repurchase mandate will expire on the earlier of the following dates: (i) the conclusion of the next AGM following the passing of the relevant resolution, unless the repurchase mandate is renewed, either unconditionally or subject to conditions, at that meeting; or (ii) the date on which the authority set out in the relevant resolution approved at a general meeting is revoked or varied by special resolution of the Shareholders in a general meeting.

The Board resolved on August 19, 2026 that, subject to market conditions, the Company may continue to implement its H Share repurchase plan pursuant to the Repurchase Mandate (the “**H Share Repurchase Plan**”), under which the Company intends to repurchase H Shares on the open market with its own funds of up to RMB100.0 million during the period until the expiration of the Repurchase Mandate. The actual repurchase price of each H Share under each repurchase shall not be higher than the average closing market price for the H Shares over the five trading days immediately preceding each repurchase by 5.0% or more. The H Shares repurchased under the Repurchase Mandate may be cancelled or held as treasury Shares.

The Company currently has healthy cash flows and a stable financial position in general, which can meet the needs of the continuous development of the Company’s business. The Board considers that the current Share price does not fully reflect the Company’s intrinsic value and business prospects, and that conducting a Share repurchase based on current conditions will demonstrate the full confidence of both the Company and the management team in its business development prospects and growth potential, ultimately benefiting the Company and creating value for Shareholders.

The Company will conduct the H Share Repurchase Plan in compliance with the Articles of Association, the Listing Rules, the Takeovers Code, the Company Law and all applicable laws and regulations to which the Company is subject.

The Directors do not propose to exercise the Repurchase Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rule 26 of the Takeovers Code and/or result in the aggregate number of Shares held by the public Shareholders falling below the minimum percentage required by the Stock Exchange.

Shareholders and potential investors of the Company should note that the exercise of the Repurchase Mandate by the Company and the implementation of the H Share Repurchase Plan will be subject to market conditions and will be at the Board’s absolute discretion and/or its authorized person(s). There is no assurance of the timing, quantity or price of any H Share repurchase or whether the Company will make any repurchases at all. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.

By order of the Board
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
杭州九源基因生物醫藥股份有限公司
FU Hang
*Executive Director, Chairman of the Board
and General Manager*

Hangzhou, the PRC, August 19, 2026

As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀), Dr. Zhou Demin (周德敏) and Dr. Huang Wenli (黃文禮) as independent non-executive directors; and (iv) Mr. Xu Feihu (徐飛虎) as an employee representative director.